Do you want to read an article? Please log in or register.
10-Years of First-Line Ipilimumab and Nivolumab in Advanced Melanoma: A Single Centre Experience
Skin Cancer
Related content
Lung, Respiratory and Thoracic Cancer
Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trial
J Thorac Oncol
Zalcman G, Madroszyk A, Guenzi E, Dayen C, Molinier O, Egenod T, Poté N, Debieuvre D, Beaucaire-Danel S, Dixmier A, Pichon E, Galland-Girodet S, Giroux-Leprieur E, Cloarec N, Cadranel J, Otto J, Romand P, Favier L, Martinez S, Mascaux C, Odier L, Cortot A, Audigier-Valette C, Langlais A, Amour E, Morin F, Antoine M, Gounant V, Westeel V, Toffart AC
doi: 10.1016/j.jtho.2026.103609
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Oncol
Scherpereel A, Baas P, Nowak AK, Tsao AS, Fujimoto N, Peters S, Mansfield AS, Popat S, Bautista Aragon Y, Talbot T, Grossi F, Kowalski D, Kaplan MA, Cardona AF, Soomro R, Hu N, Lee A, Ip V, Hung YH, Zalcman G
doi: 10.1200/JCO-25-01328
Gastrointestinal Cancer
Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649
Ann Oncol
Janjigian YY, Shitara K, Ajani JA, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary JM, Elimova E, Bruges R, Karamouzis M, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Zander T, Kowalyszyn R, Pazo-Cid R, Schenker M, Feeny K, McCraith S, Hu N, Lei M, Zhang J, Moehler M
doi: 10.1016/j.annonc.2026.02.003
Genitourinary Cancer
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial
Ann Oncol
Choueiri TK, Albigès L, McDermott DF, Hammers HJ, Escudier B, Burotto M, Plimack ER, Porta C, George S, Powles T, Donskov F, Atkins MB, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Castellano D, Grünwald V, Tomita Y, Rini BI, Jiang R, van Kooten Losio M, Lee CW, Tannir NM, Motzer RJ
doi: 10.1016/j.annonc.2026.02.017
Skin Cancer
Real-World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond
Int J Cancer
Garitaonaindia Y, Petersen SK, Guldbrandt LM, Borch TH, Ruhlmann CH, Friis RB, Luczak AA, Bastholt L, Schmidt H, Svane IM, Ellebaek E, Donia M
doi: 10.1002/ijc.70520
Lung, Respiratory and Thoracic Cancer
First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study
Lung Cancer
Shah R, Buchmeier EL, Kopp HG, Christoph DC, Griesinger F, Reck M, Hoffknecht P, Kuon J, Frost N, Grohé C, Faehling M, Luan J, Roeper J, Chesi P, Blasi M, Kimmich M, Olchers T, Bischoff H, Klotz LV, Chung I, Christopoulos P, Thomas M
doi: 10.1016/j.lungcan.2025.108702
Leukemia
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL
Blood
Burger JA, Barr PM, Robak T Prof, Owen C, Tedeschi A, Sarma A, Patten PE, Grosicki S, McCarthy H Dr, Offner F, Szafer Glusman E, Zhou C, Szoke A, Neumayr L, Dean JP, Ghia P, Kipps T
doi: 10.1182/blood.2024028205
Lung, Respiratory and Thoracic Cancer
Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small cell lung cancer: 7-year update from the phase 3 CROWN study
Ann Oncol
Shaw AT, Solomon BJ, Felip E, Bauer TM, Liu G, Goto Y, Wu YL, Soo RA, Mazieres J, Kim DW, Wang IM, Paolini J, Polli A, Rifi N, Toffalorio F, Mok TSK
doi: 10.1016/j.annonc.2026.05.692
Skin Cancer
Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study
Int J Cancer
Gutzmer R, Weichenthal M, Eigentler T, Mohr P, Sickmann T, Dücker P, Gebhardt C, Haferkamp S, Kähler KC, Meier F, Pföhler C, Sindrilaru A, Terheyden P, von Wasielewski I, Ugurel S, Ulrich J, Utikal J, Weishaupt C, Schadendorf D
doi: 10.1002/ijc.70440